Loading patent…
AssigneeHarmonia Medical Technologies, Inc.
InventorsMarvin J. Slepian, Daniel Yachia, Gill Heart, Lucjan Hronowski
Estimating the term…
Compositions have been developed to reduce or relieve prostatic obstruction. The polymers are used as an endourethral polymer liner. A biodegradable polymer liner layer can be applied to the prostatic urethra by in situ casting, or insertion and shaping of polymeric materials. This liner is preferably formed from structurally supportive, yet eventually biodegradable, polymers which further bolster and support the urethra and peri-urethral tissue during healing, eliminating the need for post-procedure catheter drainage. This step may be optional in specific clinical circumstances. Alternatively, the polymer coating may be applied to the in-situ casted structurally supportive liner, to decrease adhesion and/or provide release of drugs to enhance healing. The compositions can also be used for intra-prostatic void exclusion and space filling with adhesive and/or therapeutic polymers. Voids created as a result of intra-gland “shelling out” are filled with adhesive polymers which facilitate intraprostatic void cavity wall bonding and healing. Polymers are specifically selected to minimize inflammation, secondary bleeding and late fibrotic scarring and stricturing.
A method for treating prostate disease, chronic urethritis or strictural disease comprising
A polymeric form for application to the walls of the lower urinary tract, cavity or the urethra lining using a device having an expandable element to conform the polymeric form to the walls.
A catheter system comprising a guide wire, an expandable element to deploy a polymeric form to the walls of the lower urinary tract, cavity or the urethra lining, a polymeric form, and a covering sheath for the expandable element.
Dependencies are inferred from the claim text.